Savient Pharmaceuticals (SVNT) Posts Q1 Loss of 34c/Share

Savient Pharmaceuticals (NASDAQ: SVNT) reported Q1 EPS of ($0.34), $0.03 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $4.7 million versus the consensus estimate of $5.65 million.

For earnings history and earnings-related data on Savient Pharmaceuticals (SVNT) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Hub Group faces credibility test as Q2 report looms Sept. 1
• Marvell (MRVL) Stock: Risk/Reward Skewed to the Upside Near-Term Following Selloff, Says Analyst